Company intelligence / Profile preview

Cydan

Cambridge, Massachusetts, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Cydan specializes in identifying, de-risking, and advancing preclinical therapies for rare genetic diseases. It forms and spins out project-focused companies that proceed to clinical development. Notable spinouts include Imara (for sickle cell disease) and Vtesse (for Niemann-Pick Type C).

Therapeutic areas: Rare Diseases
Modalities: Small moleculeBiologic
Industry: Biotech

Beyond the preview

Go deeper on Cydan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cydan.

Explore the full profile